Stock Taper
SCREENER COMPARE ANY 2 STOCKS
OBX
OBSIDIAN THERAPEUTICS INC.
NASDAQ
$19.90
▼ DOWN 1.44% (-0.29)

KEY STATISTICS

Market Cap$20.70 M
52w High$49.97
52w Low$14.57
Dividend Yield—
Frequency—
P/E—
Volume1.45M
Shares Out.1.04M

COMPANY

LEADERSHIP

Madan Jagasia
CHIEF EXECUTIVE
Madan Jagasia

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 4, 2026
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
3

PRICE TARGET

Target High$42.00
Target Low$42.00
Target Median$42.00
Target Consensus$42.00

UPCOMING EARNINGS

DateAug 24, 2026
DayMonday
Rev. Est.—
AUG
24
MON

PRICE

$19.90 ▼ DOWN 1.44% (−$0.29)
$19.50$20.25$21.009:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM19.90

About Obsidian Therapeutics Inc.

https://www.obsidiantx.com ↗

A clinical-stage biopharmaceutical company developing engineered TIL therapies for solid tumors using proprietary cytoDRiVE® technology to precisely control protein function with FDA-approved drugs.

INDUSTRY

Biotechnology

A PRODUCT OBSIDIAN THERAPEUTICS INC. IS KNOWN FOR

OBX-115
OBX-115

An engineered TIL cell therapy targeting solid tumors, currently in clinical trials for advanced melanoma and non-small cell lung cancer, serving as the company's lead therapeutic candidate.

COMPETITORS

COMPETITOR
IMTX COMPARE
IOVA COMPARE
LYEL COMPARE
TIL COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
TNXT
0.07% · 604

INSIDER TRADES

★
DIRECTOR
Norkunas Matthew
Purchase · 37.7K shares
2026-08-03
★
DIRECTOR
ROSS ROBERT W.
Purchase · 37.7K shares
2026-08-03
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Jagasia Madan
Purchase · 37.7K shares
2026-08-03
★
DIRECTOR
Hagen Heidi
Purchase · 37.7K shares
2026-08-03